Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
Elisabeth Livingstone(German Cancer Research Center), Patrick Terheyden(University Hospital Schleswig-Holstein), Jochen Utikal(German Cancer Research Center), Bastian Schilling(Goethe University Frankfurt), Edgar Dippel(Klinikum Ludwigshafen), Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Uwe M. Martens(Memorial Sloan Kettering Cancer Center), Sebastian Haferkamp(University Hospital Regensburg), Alexander Roesch(Essen University Hospital), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Axel Hauschild(University Hospital Schleswig-Holstein), Silvia Körner(Heidelberg University), Thomas Eigentler(University Children's Hospital Tübingen), Carola Berking(Universitätsklinikum Erlangen), Lisa Zimmer(The University of Sydney), Beate Conrad(Fachklinik Hornheide), Jürgen C. Becker(Düsseldorf University Hospital), Jessica C. Hassel(German Cancer Research Center), Michael Fluck(Fachklinik Hornheide), Carmen Loquai(Johannes Gutenberg University Mainz), Mirjana Ziemer(University Medical Center), Leonora Schwarz(Statistisches Bundesamt), Felix Kiecker(Humboldt-Universität zu Berlin), Christian Menzer(Heidelberg University), Sabine Sell, Claus Garbe(University of Tübingen), Jan‐Christoph Simon(Leipzig University), Christine Windemuth-Kieselbach(Statistisches Bundesamt)
Cited by 113
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k